iRhythm Technologies Inc (NASDAQ:IRTC) on Thursday reported first quarter 2025 revenue of $158.7 million, up 20.3% year over year, beating the consensus of $153.38 million.
The increase was driven by growth in demand for Zio services.
The company reported an adjusted EPS loss of 95 cents, down from a loss of $1.23 a year ago, beating the consensus estimate of 98 cents.
Gross profit was $109.2 million, up 24.8% from $87.5 million during the same period in 2024, while gross margin was 68.8%, up from 66.3% during the same period in 2024.
Quentin Blackford, CEO of iRhythm, noted the company’s recent commercial launch in Japan for a total of six markets outside the U.S.
On Thursday, iRhythm announced the commercial launch of its Zio long-term continuous ECG monitoring (LTCM) system, commercially introduced in Japan as the Zio ECG Recording and Analysis System.
Guidance: iRhythm projects fiscal 2025 sales guidance of $690 million-$700 million, compared to prior guidance of $675 million-$685 million and consensus of $681.56 million.
William Blair writes, “We view updates this quarter as further validation of our thesis playing out this year as Zio AT accelerates, management executes on its land and expand strategy, and the company is seeing early positive signals in adjacent opportunities.”
Price Action: IRTC stock is up 19.1% at $129.37 at the last check Friday.
Read Next:
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。